AZTA Stock Analysis: Buy, Sell, or Hold?
AZTA - Azenta, Inc.
$16.10
-0.71 (-4.20%)
▼
5d:
-16.26%
30d:
-33.82%
90d:
-43.76%
WAIT
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Smart Money Accumulation
AZTA is down 7.3% this week, but smart money is accumulating calls. Top strike: $22.5 2026-07-17 with 6 OI. Call ratio: 62% View Scanner →
Strength: 4.9/10
Get Alerted When AZTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: AZTA is down 16.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: AZTA is down 16.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$29.89
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$18.56
13.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AZTA is currently trading at $16.09, which is considered oversold relative to its 30-day fair value range of $19.38 to $25.71. The stock's valuation (Forward PE: 27.4) is in line with its historical norms (30.1). Remarkably, the market is currently pricing in an annual earnings decline of 3.2% over the next few years. This pessimistic expectation contrasts with the company's recent 8777.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, AZTA is in a strong downtrend. The price is currently testing key support at $16.09. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $26.20 (+56.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AZTA is in a strong downtrend. The price is currently testing key support at $16.09. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $26.20 (+56.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$19.38 -
$25.71
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
Protect Your Profits
Holding AZTA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.2%)
- BULLISH: Trading 56.0% below Wall St target ($26.20)
- WARNING: Recommendation downgraded due to -16.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$19.38 -
$25.71
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$16.09
Resistance Level
$25.60
Current Trend
Strong Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
27.36
Wall Street Target
$26.20
(+56.0%)
Revenue Growth (YoY)
1.0%
Earnings Growth (YoY)
8777.8%
Profit Margin
-29.1%
Valuation Discount vs History
-3.2% cheaper
PE vs Historical
27.4 vs 30.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.2%
(market-implied from PE analysis)
1-Year Target
$16.26
(-3%)
2-Year Target
$15.74
(-6%)
3-Year Target
$15.24
(-9%)
3-Yr Target (if PE normalizes)
(PE: 27→30)
$16.76
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 27.4, Growth: 62.4%)
$56.70
(+238%)
Base:
(SPY PE: 22.0, Growth: 62.4%)
$45.67
(+172%)
Bear:
(PE: 18.7, Growth: 62.4%)
$38.82
(+131%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 27.4 to 30.1
Stabilization Target:
$18.48
(+10.0%)
PE Expansion Potential:
+10.0%
Share & Embed Analysis
Last updated: May 15, 2026 3:28 PM ET
Data refreshes hourly during market hours. Next update: 4:28 PM
Data refreshes hourly during market hours. Next update: 4:28 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AZTA showing a specific setup today?
Insider Activity (6 Months)
2
Buys
0
Sells
+
Net
NEUTRAL
Recent Transactions
Gilbert Ray Cisneros, Jr.
BUY
2026-03-03
Gilbert Ray Cisneros, Jr.
BUY
2026-01-15
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$577 | 58 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$88 | 53 HOLD |
|
RMD
ResMed Inc |
BUY
19 analysts |
$271 | 59 HOLD |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$180 | 49 HOLD |
|
COO
The Cooper Companies, Inc |
BUY
19 analysts |
$91 | 64 BUY |
Advanced AZTA Option Strategies
Professional options setups generated by AI based on today's AZTA price and gamma walls.
